Article

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine

2021-08-31

Abstract excerpt

With the evidence of waning immunity of the BNT162b2 vaccine, a national third dose vaccination campaign was initiated in Israel during August 2021; other countries have announced their intention to administer a booster shot as well. Leveraging data from Maccabi Healthcare Services, we conducted a preliminary retrospective study aimed at evaluating initial short-term effectiveness of a three dose versus a two dose...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cf05cdab-f634-5e22-96ee-c57e891c97d3
DOI: 10.1101/2021.08.29.21262792

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 VaccineDOI 10.1101/2021.08.29.21262792Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidenceSemantic proximity Read

Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in IsraelSemantic proximity Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarSemantic proximity Read

Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in IsraelSemantic proximity Read

Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort studySemantic proximity Read

BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 PatientsSemantic proximity Read

Protection against omicron severe disease 0-7 months after BNT162b2 boosterSemantic proximity Read

Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccineSemantic proximity Read

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infectionsSemantic proximity Read

Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary StudySemantic proximity Read